Figshare
open access
CC BY 4.0
Supplementary file 3_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf
case-reportcholangitisgenetic-immunologyimmune-check-point-inhibitorliver-biopsytocilizumabursodeoxycholic-acid
Introduction Immune checkpoint inhibitors (ICIs) have revolutionized treatment of multiple malignancies, nevertheless, their clinical use can be associated with adverse events (AE). ICI-induced cholangitis (ICI-C) belongs to rare AEs. Poor response to glucocorticosteroids (GCS) is observed, deaths
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
2026-10-27T09:40:42Z https://api.figshare.com/v2/oai The request includes illegal arguments, is missing required arguments, includes a repeated argument, or values for arguments have an illegal syntax.
Related documents
- Supplementary file 4_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf#1459368
- Supplementary file 2_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf#1459371
- Supplementary file 6_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf#1459370
- Supplementary file 7_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf#1459367
- Supplementary file 1_Case Series: Severe cholangitis as an immune checkpoint inhibitor induced adverse event in four cases: management and treatment options including tocilizuab and ursodeoxycholic acid.pdf#1459373
Record · ID 1459372 · SHA-256 db04a2070c7d55da
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive